Phase II trial evaluates cystectomy eligibility in cisplatin-ineligible muscle-invasive bladder cancer patients, suggesting implications for treatment.
Key Points
To assess the efficacy of neoadjuvant nivolumab alone or in combination with ipilimumab in cisplatin-ineligible patients with muscle-invasive bladder cancer.
Conducted a phase II trial with cohorts receiving nivolumab alone or ipilimumab/nivolumab.
Primary endpoint was eligibility for cystectomy within 60 days after last treatment.
Utilized correlative analyses and compared results with the PURE-01 trial.
12 out of 15 patients in the nivolumab cohort were eligible for cystectomy within 60 days.
8 out of 15 patients in the ipilimumab/nivolumab cohort were eligible for cystectomy.
12-month recurrence-free survival was 79% for nivolumab and 61% for ipilimumab/nivolumab.